{
    "2021-01-18": [
        [
            {
                "time": "2023-10-10",
                "original_text": "医药生物：中国创新药是否到了国际化的拐点？",
                "features": {
                    "keywords": [
                        "医药生物",
                        "中国创新药",
                        "国际化",
                        "拐点"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "高瓴资本概念股普遍活跃，广联达、国瓷材料、凯莱英、公牛集团走强",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "概念股",
                        "广联达",
                        "国瓷材料",
                        "凯莱英",
                        "公牛集团",
                        "走强"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "科技",
                        "医药",
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "医药行业政策点评：第四批集采开标在即 持续看好创新药及相关产业链",
                "features": {
                    "keywords": [
                        "医药行业",
                        "政策",
                        "第四批集采",
                        "创新药",
                        "产业链"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "医药生物：CXO景气度持续高涨 重点推荐药明康德、凯莱英等",
                "features": {
                    "keywords": [
                        "医药生物",
                        "CXO",
                        "景气度",
                        "药明康德",
                        "凯莱英"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}